Travelers' diarrhea (TD) has historically been a common illness among visitors to developing nations. Although recent studies indicate decreasing incidence of TD among short-term travelers, a systematic review of illness among long-term travelers, including deployed military personnel, has not been conducted in more than 10 years. We conducted a literature search of studies published between 2005 and 2015 that evaluated TD in populations of deployed military personnel or similar long-term travelers (travel ≥1 month) to developing nations. Our literature search identified 28 studies for inclusion. We found that the incidence of TD remained high (10% clinical incidence, 30% self-reported incidence), with variability depending on region of travel and similar rates in both military and civilian long-term travelers. Bacteria (Escherichia coli, Campylobacter, Shigella, and Salmonella species) were the most commonly identified enteropathogens. Fifty percent of affected individuals experienced lost ability to work and 5% required hospitalization. This systematic review demonstrates that among deployed military personnel and longterm travelers, TD remains a prevalent disease that can significantly impact individual readiness for duty. These data demonstrate that to maintain operational readiness among deployed personnel, a focus on vigilance for disease and early treatment of cases is vital.
INTRODUCTION
Acute infectious diarrhea remains one of the most common ailments of travelers to underdeveloped and developing regions of the world. The etiology of travelers' diarrhea (TD) is predominantly bacterial, with enterotoxigenic Escherichia coli, Campylobacter jejuni, Shigella, and Salmonella species most commonly implicated pathogens that infrequently cause illness in developed nations due to improved methods of sanitation. [1] [2] [3] In addition to causing the acute infectious gastroenteritis, pathogens commonly isolated from TD cases have also been associated with a number of postinfectious diarrheal sequelae, most notably irritable bowel syndrome and functional dyspepsia. 4, 5 Despite heightened awareness, pretravel recommendations for TD, and effective treatment options, TD accounts for 335 of every 1,000 medical visits by returned travelers. 6 Within the military, TD has long played a major role in operations and remains a significant illness among deployed personnel. 1, 7 On average, acute TD can preclude a service member from being able to perform his or her duties for 3 to 10 days, and given the high rate of infection among deployed personnel, cumulatively, TD can lead to a significant impact on operational efforts. 1, 8 A systematic review of TD epidemiology published between 1990 and 2005 found that approximately 30% of deployed military personnel and similar populations of longterm travelers suffer from acute diarrheal illness, with the greatest geographic distribution in the Middle East; however, there have been no updates to those estimates over the past 10 years. 1 Recent studies of self-reported illness among U.S. troops participating in Operations Iraqi Freedom and Enduring Freedom published since that time have demonstrated alarming cumulative incidences of >75% and >50%, respectively. 9, 10 These findings, along with changes in operational deployments, travel destinations and habits, and emerging global economies over the last 10 years necessitate a re-evaluation of TD epidemiology. The aim of this study is to review the past decade of published data on the incidence, etiology, and impact of TD on long-term travelers, including deployed U.S. military personnel. or diarrhea) with the following terms, while eliminating duplicates: epidemiology, etiology, military, Peace Corps, expatriate, incidence, burden, morbidity, and treatment. In addition, MEDLINE searches were conducted using major medical subject headings determined from articles known to be eligible. Studies were selected based on exclusion and inclusion criteria. One reviewer screened all publications and reports for possible inclusion based on eligibility criteria. If eligibility could not be determined from title and/or abstract alone, the full text was retrieved and evaluated. Publications classified as review, in non-English language, editorials, case reports, or determined to be irrelevant after investigator review were excluded. Data from retrieved articles, technical reports, and doctoral dissertations were abstracted based on inclusion and exclusion criteria and verified. Review articles were obtained for hand searching bibliographies for articles of possible relevance and inclusion.
Studies on deployed U.S. military personnel and similar long-term travel populations were reviewed for inclusion criteria. Similar traveler populations were defined as residents of a developed country travelling abroad to a developing country. Long-term travel was defined as travel for ≥1 month. All studies involving deployed U.S. military personnel, regardless of travel duration, were considered for inclusion. Studies involving business travel and civilian short-term travelers (<1 month of travel abroad) were excluded. Analyses with duplicate study populations were also excluded. Included studies were categorized to geographic regions of sub-Saharan Africa, Latin America and the Caribbean, Southeast Asia, and the Middle East based on the reported regions of travel. Studies specific to pathogens not implicated in TD or with undefined geographic regions were excluded.
Using a pretested, standardized abstraction form, data from retrieved articles and reports were abstracted. The primary outcomes of interest were quantitative and qualitative measures of etiology and incidence of diarrheal disease and its associated treatment and morbidity. Pathogen prevalence was abstracted as a percentage of total cases. The total number of diarrheal cases was abstracted along with the size of the study population and study period used to compute diarrheal prevalence or incidence. In prophylaxis trials, estimates of disease were abstracted for only the placebo group. Pathogen prevalence and diarrheal incidence were stratified by geographic region and 95% confidence intervals estimated, as previously described. 1, 11 
RESULTS
A total of 464 studies published between 2005 and 2015 were identified from electronic search databases and citations. Of the 193 studies potentially eligible for inclusion based on initial review, 28 fulfilled all criteria and were included after full evaluation ( Fig. 1 ; Table I ). Three studies were stratified as "multiple" for geographic region, due to overlapping regions of travel and an inability to stratify inci-dence estimates for each included region. Additionally, data abstracted from one unpublished study were abstracted, and because it was validated internally by the military, it was deemed appropriate for inclusion in the analysis.
Heterogeneity in the estimates of TD incidence was observed across studies ( χ 2 heterogeneity statistic, p <0.001). Incidence estimates based on active surveillance were 3-fold higher among studies assessing disease by active surveillance with self-reporting by survey compared to those utilizing passive surveillance methods (30.3 vs. 10.7 per 100 person months, respectively; Table II ). Fourteen studies reported data on the probability that an individual traveler sought treatment for the TD episode. Two of these included estimates of self-reported incidence and clinic-based incidence (visits to a medical treatment facility). Overall, a median of 30% (interquartile range [IQR]: 20-45%) of individuals with TD sought treatment.
Summary estimates of pathogen prevalence by region are detailed in Table III . Overall, regional differences in pathogen distributions were found for enterotoxigenic E. coli (ETEC), enteroaggregative E. coli (EAEC), Campylobacter, Shigella, and Salmonella species, and norovirus ( p < 0.01 for each pathogen). These differences are attributable to the high prevalence of Campylobacter and Salmonella in southeast Asia, the relatively lower prevalence of EAEC in Latin America/Caribbean, and the high prevalence of Shigella and low prevalence of ETEC in the Middle East. Two studies from sub-Saharan Africa identified ETEC, EAEC, and Campylobacter as important pathogens in this region, accounting for approximately 36%, 36%, and 20% of cases, respectively. Salmonella was reported in studies from each of the regions and was highest in southeast Asia (16%) compared with regions of the Middle East (1%) and sub-Saharan Africa (2.5%). Other bacterial and viral pathogens were inconsistently reported across studies within regions; however, pooled summary estimates of EAEC prevalence were 4% to 17%, norovirus 2% to 16%, and rotavirus 2% to 6%. Multiple pathogens per TD illness were also common and more prevalent in Latin America/Caribbean (22%) compared to the Middle East (7%).
Nineteen studies reported data on disease severity and outcomes (Table IV) . Three studies reported on the probability of treatment failure among those provided antibiotic treatment, with a median estimate of 20% (range: 10-28%). [12] [13] [14] Although case definitions for treatment failure varied, they generally involved either worsening of symptoms after 24 hours, no improvement of symptoms after 72 to 96 hours, relapse, or documented antibiotic resistance. In 11 studies, the median probability of a person with diarrhea being placed sick-in-quarters (SIQ) or incapacitated because of the illness was 23% (IQR: 13-34%) (John W. Sanders, unpublished data). 9, [13] [14] [15] [16] [17] [18] [19] [20] [21] Seven studies reported a median of 2.0 days (IQR: 1.3-2.5 days) of symptoms pretreatment, with post-treatment duration ranging from 1.5 to 3 days. Antibiotic treatment in combination with loperamide appeared to shorten the posttreatment duration in two studies compared to the single study of antibiotic alone (median of 1.8 and 3.0 days, respectively). Three studies reported a median time to last unformed stool (TLUS) without loperamide treatment as 0.4 days (range: 0.3-1.8 days).
DISCUSSION
We found that while there was significant variability in incidence (3-56 per 100-person months) across studies and regions, the incidence of TD among deployed military and long-term travelers has remained high in the decade since the last systematic review. This finding is confounded by a lack of studies across all regions. Overall, the incidence of TD was higher with active surveillance from self-reported survey studies versus passive surveillance from clinic-based studies (10.7 versus 30.3 clinic visits per 100 person-months, respectively), which is consistent with prior studies. 1 This finding indicates that a sizeable number of cases of TD do not present to medical care, representing the possibility of lost duty hours among deployed personnel that could be mitigated by medical treatment shortening the duration of illness.
In studies where stool samples were tested during the acute TD illness, enteropathogens were identified in almost 60% of cases, a figure higher than previously reported. 1 It is possible that the higher rates of recovery are indicative of better test techniques and recovery methods, such as molecular testing; however, microbiologic methods were not directly assessed in this study. Among those samples positive for pathogens on testing, ETEC, Campylobacter, and Shigella appear to cause the highest proportion of TD in this population; however, norovirus may be under-reported due to the lack of appropriate microbiological methods and/or case definitions.
In addition, pathogen prevalence across regions and over time could reflect design differences and change in microbiologic methods between studies. Studies in southeast Asia had higher pathogen recovery rates than other regions (79% versus 61%). Though not statistically significant ( p = 0.14), this is similar to estimates reported by Riddle et al and could be related to study design characteristics or other factors. 1 Among deployed military personnel, approximately one in three U.S. service members experiencing TD reported seeking medical care, which is higher than prior reports. 1 It may be that the importance of diarrheal treatment is better communicated pretravel; however, limited data are available to support the rationale for this apparent change.
Although the drivers of care-seeking behavior are poorly understood, they do not seem to be related to disease severity. 9, 12, 13, 22 Given the known ability of effective treatment to reduce the duration of TD, 23, 24 this represents a potential opportunity for improvement in disease management, particularly in deployed populations where faster return to daily activities could have large impacts on operational readiness. Although TD is viewed as a relatively mild disease, we observed significant morbidity associated with the acute illness, with 50% reporting a decrease in one's ability to work, 24% being SIQ or incapacitated, and 2% requiring hospitalization (data not shown). This finding highlights that focusing on prevention and avoidance of disease remains paramount. Moreover, as food hygiene education has shown limited efficacy in prevention, advancing prophylaxis techniques, and immunization should be priorities for controlling TD among deployed personnel. TD remains a significant burden of disease and driver of morbidity among deployed military personnel and long-term travelers. Although others have reported a decreasing TD rate among short-term travel populations, such decreases are not readily apparent among long-term travelers based on the data from this study. 6 Furthermore, military populations are a unique subset of the general travel population. As a portion of military personnel included traveled for less than 1 month, comparisons with studies of civilian TD should be interpreted cautiously. In addition, only studies on U.S. military personnel were included, so our findings may not be generalizable to armed forces personnel from other nations. Although decrements in travel activity for the general traveler may limit leisure activities, for the deploying military, the high incidence of TD has the potential to negatively impact mission operations. The importance of vigilance for disease, encouragement of seeking care when affected, and assurance of appropriate treatment of cases in deployed populations cannot be understated given the ability of antibiotic treatment combined with an antimotility agent to significantly reduce disease duration. 24 As our study demonstrates the ongoing impact of TD, clinical practice guidelines to standardize treatment across branches of military service are greatly needed and will be a significant advancement in military healthcare to improve operational readiness. 
